查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884057

子宮頸癌疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Cervical Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

子宮頸癌疫苗市場成長驅動因子

由於子宮頸癌發生率上升、HPV預防意識增強以及全球疫苗接種率提高，全球子宮頸癌疫苗市場正經歷顯著增長。根據最近的一項研究，2024 年該市場規模為 108.6 億美元，預計到 2025 年將達到 123.6 億美元。預計到 2032 年將進一步成長至 370.1 億美元，預測期內複合年增長率 (CAGR) 為 17.0%。北美地區在 2024 年以 34.71% 的市佔率領先，這主要歸功於其較高的疫苗接種率、完善的醫療保健基礎設施以及支持快速獲得 HPV 疫苗的監管審批。

子宮頸癌是全球女性第四大常見癌症，主要由高危險型人類乳突病毒 (HPV) 的持續感染引起。感染 HIV 的女性罹患子宮頸癌的風險是未感染 HIV 女性的六倍，凸顯了預防策略的必要性。 Cervarix、Gardasil 和 Secolin 等疫苗可提供對 HPV 的免疫力，目前已被廣泛接受，作為針對子宮頸癌的低風險、長期預防措施。

市場驅動因素與機會

市場成長的驅動因素是子宮頸癌發生率的上升，尤其是在中低收入國家 (LMIC)，這些國家的公眾意識、篩檢和預防干預措施有限。根據世界衛生組織 2024 年 3 月的數據，2022 年全球將通報約 66 萬例新增子宮頸癌病例，造成約 35 萬人死亡。這種成長趨勢正在推動對有效疫苗接種計劃的需求，尤其是針對青少年的疫苗接種計劃。

另一個關鍵驅動因素是支持廣泛接種疫苗的公私部門合作關係。政府、非政府組織和製藥公司之間的合作，例如2024年Unitaid-Gavi合作項目，正在幫助改善服務不足地區獲得子宮頸癌疫苗的機會。這些努力有助於提高公眾意識，支持符合文化背景的疫苗接種活動，並解決醫療保健服務取得的社會經濟差異。

此外，研發投資和強大的治療性疫苗研發管線正在為市場擴張創造機會。目前，全球有20多種治療性HPV疫苗候選產品正在進行臨床開發，凸顯了新產品在補充疫苗接種和針對早期或復發性子宮頸癌方面的潛力。

市場限制因素與挑戰

儘管市場成長強勁，但仍有一些因素限制著市場發展。疫苗猶豫和錯誤訊息是主要障礙，尤其是在較保守的社會。疫苗會促使不孕和不良反應的誤解促使青少年疫苗接種率低下，並限制了整體市場滲透率。根據 Ecancer Medical Science（2024 年 8 月）報告，儘管疫苗的有效性和安全性已得到證實，但錯誤訊息仍在持續降低疫苗接種率。

中低收入國家醫療基礎設施的匱乏也是一項挑戰。維持 HPV 疫苗的冷鏈物流和建立廣泛的疫苗接種中心需要大量資源。此外，HPV DNA 檢測和篩檢的高昂基礎設施成本限制了資源匱乏地區疫苗的可近性，從而影響了市場成長。

市場趨勢

子宮頸癌疫苗市場的一個顯著趨勢是單劑疫苗，它簡化了接種程序並提高了患者的依從性。世界衛生組織免疫實務策略諮詢專家小組（SAGE，2022 年 4 月）證實，單劑疫苗可有效預防 HPV 感染，有助於提高那些難以堅持接種多劑疫苗地區的疫苗接種覆蓋率。

美國、澳洲和英國等已開發國家正在推行性別中立的疫苗接種計劃，並將接種範圍擴大到男孩，這有助於降低HPV感染率和相關癌症的發生率。此外，國產且價格合理的疫苗的出現，例如印度的CERVAVAC（2023年），提高了疫苗的可及性和可負擔性，尤其是在資源匱乏的地區。

市場區隔分析

  • 依疫苗類型：在FDA和WHO的批准、廣泛應用以及政府支持計畫的推動下，預防性疫苗將在2024年佔主導地位。由於Lenti-HPV-07和CAN-2409等新型候選疫苗的臨床開發，治療性疫苗預計將以更高的複合年增長率成長。
  • 按技術：分子疫苗佔領先地位，其特點是安全性和有效性，利用病毒樣顆粒（VLPs）。 由於載體疫苗能夠誘發持久的免疫反應，其市場規模持續成長。
  • 分銷管道：醫院藥房佔主導地位，因為患者會前往診所接種疫苗。政府和機構的供應管道在國家疫苗接種計畫中也扮演著重要角色。

區域展望

  • 北美：預計到2024年，市場規模將達到37.7億美元，其中美國將引領市場成長。高發病率、先進的醫療設施和疫苗接種運動是推動市場成長的主要因素。
  • 歐洲：成熟的醫療體系、集中採購以及旨在提高疫苗接種覆蓋率的宣傳活動預計將推動市場穩步成長。
  • 亞太地區：該地區是成長最快的地區，這主要得益於政府主導的各項舉措，例如印度的 "終結子宮頸癌使命" 以及宣傳活動的增加。
  • 拉丁美洲、中東和非洲：儘管公共衛生措施正在擴大疫苗接種覆蓋範圍，但由於公眾意識薄弱和基礎設施不足等問題，預計成長速度將較為緩慢。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家和地區子宮頸癌盛行率（2024 年）
  • 主要國家及地區監理概況
  • 主要公司產品線分析
  • 主要產業趨勢－併購與合作
  • 主要公司新產品發布

第五章：全球子宮頸癌疫苗市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 按疫苗類型劃分
    • 預防性疫苗
    • 治療性疫苗
  • 市場分析、洞察與預測 - 按技術劃分
    • 分子生物學疫苗
    • 載體疫苗
    • 其他
  • 市場分析、洞察與預測 - 按分銷管道劃分
    • 醫院
    • 政府及機構供應
    • 其他
  • 市場分析、洞察與預測 - 按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

章節第六章：北美子宮頸癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲子宮頸癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區子宮頸癌疫苗市場分析、洞察與預測（2019-2032）

  • 按…劃分國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲子宮頸癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章 中東與非洲子宮頸癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 其他中東和非洲國家

章節11：競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • 葛蘭素史克公司 (GSK plc.)
    • 默克公司 (Merck & Co., Inc.)
    • 印度血清研究所 (Serum Institute of India Pvt. Ltd.)
    • Theravectys
    • ViciniVax
    • 華生生物技術股份有限公司 (Walvax Biotechnology Co., Ltd.)
    • 廈門新華生技有限公司 (Xiamen Innovax Biotech CO., LTD.)
Product Code: FBI113609

Growth Factors of cervical cancer vaccines Market

The global cervical cancer vaccines market is experiencing significant growth due to rising prevalence of cervical cancer, increasing awareness of HPV prevention, and expanded vaccination coverage worldwide. According to recent insights, the market was valued at USD 10.86 billion in 2024, is projected to reach USD 12.36 billion in 2025, and is expected to grow to USD 37.01 billion by 2032, reflecting a CAGR of 17.0% during the forecast period. North America dominated the market in 2024 with a 34.71% share, driven by high adoption rates, established healthcare infrastructure, and regulatory approvals supporting rapid access to HPV vaccines.

Cervical cancer, the fourth most common cancer in women globally, primarily develops due to persistent infection with high-risk types of human papillomavirus (HPV). Women living with HIV have a six-fold higher risk of developing cervical cancer compared to HIV-negative women, emphasizing the need for preventive strategies. Vaccines such as Cervarix, Gardasil, and Cecolin provide immunity against HPV and are currently the mainstay for prevention, offering targeted, low-risk, and long-term protection against cervical cancer.

Market Drivers and Opportunities

The market growth is fueled by the rising prevalence of cervical cancer, particularly in low- and middle-income countries (LMICs) where awareness, screening, and preventive interventions are limited. According to WHO data in March 2024, around 660,000 new cases of cervical cancer were reported in 2022, leading to approximately 350,000 deaths globally. The increasing incidence has heightened the demand for effective vaccination programs, especially in adolescent populations.

Another significant driver is public-private partnerships supporting widespread vaccination. Collaborations between governments, NGOs, and pharmaceutical companies, such as the 2024 partnership between Unitaid and Gavi, are improving access to cervical cancer vaccines in underserved regions. These initiatives enhance public awareness, support culturally appropriate vaccination campaigns, and address socio-economic disparities in healthcare access.

Moreover, R&D investment and a robust pipeline of therapeutic vaccines are creating opportunities for market expansion. Over 20 therapeutic HPV vaccine candidates are currently in clinical development globally, highlighting the potential for new products to supplement preventive vaccination and target early-stage or recurrent cervical cancer.

Market Restraints and Challenges

Despite strong growth, several factors constrain the market. Vaccine hesitancy and misinformation are major barriers, especially in conservative societies. Myths suggesting vaccines cause infertility or adverse effects reduce adoption rates among adolescents, limiting the overall market penetration. According to Ecancer Medical Science (August 2024), misinformation continues to lower vaccination uptake despite proven efficacy and safety.

Limited healthcare infrastructure in LMICs also poses challenges. Maintaining cold-chain logistics for HPV vaccines and establishing widespread vaccination centers require substantial resources. Additionally, high costs of HPV DNA testing and infrastructure for screening further restrict vaccine access in resource-limited settings, impacting market growth.

Market Trends

A notable trend in the cervical cancer vaccines market is single-dose vaccination, simplifying immunization schedules and enhancing patient compliance. WHO's Strategic Advisory Group of Experts on Immunization (SAGE, April 2022) confirmed that a single dose provides effective protection against HPV, improving vaccination coverage in regions where multi-dose adherence is challenging.

Gender-neutral vaccination programs are emerging in developed countries such as the U.S., Australia, and the U.K., expanding coverage to boys to reduce overall HPV transmission and incidence of related cancers. Additionally, the rise of indigenous and affordable vaccines, like India's CERVAVAC (2023), is improving access and affordability, particularly in low-resource regions.

Segmentation Analysis

  • By Vaccine Type: Preventive vaccines dominate in 2024 due to FDA and WHO approvals, widespread adoption, and government-backed programs. Therapeutic vaccines are projected to grow at a higher CAGR due to clinical development of novel candidates like Lenti-HPV-07 and CAN-2409.
  • By Technology: Molecular-based vaccines lead, leveraging virus-like particles (VLPs) for safety and efficacy. Vector-based vaccines are growing due to their ability to trigger long-lasting immune responses.
  • By Distribution Channel: Hospital pharmacies dominate due to patient visits for vaccination procedures. Government and organizational supply channels also play a significant role in national immunization programs.

Regional Outlook

  • North America: Market size of USD 3.77 billion in 2024, led by the U.S., driven by high prevalence, advanced healthcare facilities, and vaccination campaigns.
  • Europe: Stable growth with mature healthcare systems, centralized procurement, and awareness programs increasing vaccine uptake.
  • Asia Pacific: Fastest-growing region, supported by government initiatives such as India's 'Cervical Cancer Mukt Bharat' mission and rising awareness programs.
  • Latin America & Middle East & Africa: Moderate growth due to limited awareness and infrastructure challenges, though public health initiatives continue to expand vaccination reach.

Competitive Landscape

The market is concentrated with GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd. dominating. GSK leads with Cervarix, Merck with Gardasil, and the Serum Institute expands access through CERVAVAC. Other players such as THERAVECTYS, ViciniVax, and Walvax Biotechnology focus on therapeutic vaccine development and strategic R&D investments to capture market share.

Conclusion

With a market size of USD 10.86 billion in 2024, rising to USD 12.36 billion in 2025, and projected to reach USD 37.01 billion by 2032, the global cervical cancer vaccines market is poised for rapid expansion. Key drivers include increasing HPV prevalence, preventive vaccination programs, single-dose innovations, and gender-neutral strategies. Strategic partnerships, affordable vaccines, and therapeutic vaccine pipelines will shape market growth over the forecast period.

Segmentation By Vaccine Type

  • Preventive Vaccine
  • Therapeutic Vaccine

By Technology

  • Molecular-based
  • Vector-based
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Government & Organization Supply
  • Others

By Region

  • North America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cervical Cancer, by Key Countries/Region, 2024
  • 4.2. Overview of Regol atory Scenario, by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.5. New Product Launches, By Key Players

5. Global Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 5.1.1. Preventive Vaccine
    • 5.1.2. Therapeutic Vaccine
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Molecol ar-based
    • 5.2.2. Vector-based
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals
    • 5.3.2. Government & Organization Supply
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 6.1.1. Preventive Vaccine
    • 6.1.2. Therapeutic Vaccine
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Molecol ar-based
    • 6.2.2. Vector-based
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals
    • 6.3.2. Government & Organization Supply
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 7.1.1. Preventive Vaccine
    • 7.1.2. Therapeutic Vaccine
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Molecol ar-based
    • 7.2.2. Vector-based
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals
    • 7.3.2. Government & Organization Supply
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 8.1.1. Preventive Vaccine
    • 8.1.2. Therapeutic Vaccine
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Molecol ar-based
    • 8.2.2. Vector-based
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals
    • 8.3.2. Government & Organization Supply
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 9.1.1. Preventive Vaccine
    • 9.1.2. Therapeutic Vaccine
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Molecol ar-based
    • 9.2.2. Vector-based
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals
    • 9.3.2. Government & Organization Supply
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 10.1.1. Preventive Vaccine
    • 10.1.2. Therapeutic Vaccine
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Molecol ar-based
    • 10.2.2. Vector-based
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospitals
    • 10.3.2. Government & Organization Supply
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc.
    • 11.2.3. Serum Institute of India Pvt. Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc.
    • 11.2.4. THERAVECTYS
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc.
    • 11.2.5. ViciniVax
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc.
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT,Etc.
    • 11.2.7. Xiamen Innovax Biotech CO., LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 2: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 3: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 6: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 7: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 10: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 11: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 14: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 15: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 18: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 19: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2019-2032
  • Table 22: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2019-2032
  • Table 23: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Cervical Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024 & 2032
  • Figure 3: Global Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024 & 2032
  • Figure 4: Global Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Cervical Cancer Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 7: North America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 8: North America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 9: North America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 10: North America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Cervical Cancer Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Cervical Cancer Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 15: Europe Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 16: Europe Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 17: Europe Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 18: Europe Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 23: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 24: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 25: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 26: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 31: Latin America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 32: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 33: Latin America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 34: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2024 & 2032
  • Figure 39: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2024
  • Figure 40: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2024 & 2032
  • Figure 41: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Technology, 2024
  • Figure 42: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Cervical Cancer Vaccines Market Share (%), By Company, 2024